Corbus Pharmaceuticals Holding (CRBP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $69.86M
Last updated: Nov 17, 2026 at 4:37 PM ET
Corbus Pharmaceuticals Holding (CRBP) Statistics
Corbus Pharmaceuticals Holding (CRBP) has a market cap of $69.86M and an enterprise value of $42.79M. It kept -3162.62% of revenue as net income over the last 12 months. Its share count is up 69.31% from a year earlier.
Total Valuation
Enterprise value is 38.75% below the market cap, as cash exceeds debt.
| Market Cap | $69.86M |
|---|---|
| Enterprise Value | $42.79M |
| Latest price (Nov 17, 2026) | $3.01 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 12.4x and 0.7x. Its year-end P/S ranged from 9.7x to 949.5x from 2016 to 2025.
| P/S Ratio | 12.4x |
|---|---|
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 72.81% over 52 weeks and trades 43.84% below its 50-day average.
| Beta (1Y) | 1.83 |
|---|---|
| 52-Week Change | -72.81% |
| 1-Month Change | -32.51% |
| 3-Month Change | -69.87% |
| 6-Month Change | -67.10% |
| 5-Year Change | -85.95% |
| 10-Year Change | -97.49% |
| Total Return (1Y) | -72.81% |
| Total Return (3Y CAGR) | -13.24% |
| Total Return (5Y CAGR) | -35.82% |
| Return vs SPY (1Y) | -86.50% |
| Max Drawdown (1Y) | -76.46% |
| Max Drawdown (3Y) | -95.35% |
| Sharpe Ratio (1Y) | -1.68 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $5.36 |
| 200-Day Average | $8.31 |
| 52-Week Range | $2.81 to $12.88 |
| RSI (14 Days) | 30.3 |
| Average Volume (20 Days) | 1.15M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.40x current liabilities, and total debt is 0.04x shareholder equity.
| Current Ratio | 3.40x |
|---|---|
| Quick Ratio | 3.40x |
| Debt / Equity | 0.04x |
Returns and Efficiency
Return on invested capital is -106.71% over the last 12 months, against a 5-year average of -41.35%.
| Return on Equity (ROE) | -188.58% |
|---|---|
| Return on Assets (ROA) | -130.05% |
| Return on Invested Capital (ROIC) | -106.71% |
| Return on Capital Employed (ROCE) | -135.08% |
| ROIC (5Y Average) | -41.35% |
| Asset Turnover | 0.04x |
Scores
CRBP has an Altman Z-Score of -8.76, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -8.76 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $5.05M over the last 12 months is down 42.77% from the 12 months before.
| Revenue | $5.05M |
|---|---|
| Revenue Growth (YoY) | -42.77% |
| Gross Profit | $5.05M |
| Operating Income | -$121.28M |
| Pretax Income | -$160.00M |
| Net Income | -$159.84M |
| EBITDA | -$120.03M |
| EBIT | -$118.78M |
| Reported EPS (TTM) | -$6.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 68.97% of the $122.90M in total assets.
| Cash and Equivalents | $30.25M |
|---|---|
| Total Debt | $3.18M |
| Net Cash | $27.07M |
| Net Cash Per Share | $1.30 |
| Working Capital | $83.98M |
| Shareholder Equity | $84.76M |
| Book Value Per Share | $4.07 |
| Total Assets | $122.90M |
| Total Liabilities | $38.14M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $34.00K of capital spending, operating cash flow left -$92.39M of free cash flow.
| Operating Cash Flow | -$92.36M |
|---|---|
| Capital Expenditures | $34.00K |
| Free Cash Flow | -$92.39M |
| FCF Per Share | -$4.78 |
| Depreciation and Amortization | $1.65M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2399.76%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2399.76% |
| Pretax Margin | -3165.75% |
| Net Margin | -3162.62% |
| EBITDA Margin | -2375.05% |
| EBIT Margin | -2350.24% |
| FCF Margin | -1828.08% |
Dividends and Yields
CRBP does not pay a dividend.
| Buyback Yield | -162.95% |
|---|---|
| Shareholder Yield | -162.95% |
Stock Splits
The last split was a 1-for-30 reverse split on Feb 14, 2023.
| Last Split Date | Feb 14, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 9 similar companies, CRBP has the 5th highest P/S.
P/S RatioPeer median 12.3x
ROICPeer median -144.80%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +17.59%
| P/S Ratio | 12.4x vs 12.3x median |
|---|---|
| ROIC | -106.71% vs -144.80% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -42.77% vs +17.59% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CRBP
What is CRBP's market cap?
Corbus Pharmaceuticals Holding has a market cap of $69.86M. Its enterprise value, which adds debt and subtracts cash, is $42.79M.
How many shares of CRBP are outstanding?
Corbus Pharmaceuticals Holding has 20.84M shares outstanding. The count is up 69.31% from a year earlier.
Does CRBP pay a dividend?
No. Corbus Pharmaceuticals Holding does not pay a dividend.
How much debt does CRBP have?
Corbus Pharmaceuticals Holding has $3.18M of total debt and $30.25M of cash and equivalents, a net cash position of $27.07M.
CRBP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors